Sprifermin (rhFGF18) modulates extracellular matrix turnover in cartilage explants ex vivo
Sign Up to like & getrecommendations! Published in 2017 at "Journal of Translational Medicine"
DOI: 10.1186/s12967-017-1356-8
Abstract: BackgroundSprifermin (recombinant human fibroblast growth factor 18) is in clinical development as a potential disease-modifying osteoarthritis drug (DMOAD). In vitro studies have shown that cartilage regenerative properties of sprifermin involve chondrocyte proliferation and extracellular matrix… read more here.
Keywords: cartilage explants; ecm turnover; turnover; extracellular matrix ... See more keywords